Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.42 |
| ▸ | RXRA | P19793 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879131 | 0.83 | ACHE (0.40) | ALDH1A1SMN1; SMN2ACHEHTR1ASLC6A2 | |
| SCHEMBL10052629 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL14345864 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL10821843 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GRIN1GRIN2BRXRASMN1; SMN2 | |
| SCHEMBL14525531 | 0.80 | CYP2A6 (0.45) | ALDH1A1GRIN1GRIN2BRXRASMN1; SMN2 | |
| SCHEMBL28043602 | 0.78 | GRIN2B (0.40) | ALDH1A1GRIN1GRIN2BRXRASMN1; SMN2 | |
| SCHEMBL900483 | 0.78 | MEN1 (0.52) | ALDH1A1GRIN1GRIN2BRXRASMN1; SMN2 | |
| SCHEMBL7682113 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL15133865 | 0.78 | ACHE (0.65) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL15173401 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2021263205-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| WO-2020249796-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249799-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249792-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098207-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| EP-2755965-B1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017006282-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017006270-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017006271-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2621922-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041858-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | ALDH1A1 2444/4885GRIN1 4616/4885GRIN2B 4652/4885 |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | ALDH1A1 208/4885GRIN1 1393/4885GRIN2B 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.